This inventor holds 1 USPTO granted patent, plus 1 CIPO patent and 1 EPO patent. Top assignee: Suven Life Sciences Limited. Active years: 2015.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2015
Title: Anil Kashinath Chindhe: Innovator in Pharmaceutical Chemistry
Introduction
Anil Kashinath Chindhe is an accomplished inventor based in Hyderabad, Telangana, India. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of novel compounds with potential therapeutic applications.
Latest Patents
Anil Kashinath Chindhe holds a patent for "Sulfone compounds as 5-HT6 receptor ligands." This invention includes novel sulfone compounds characterized by their ability to interact with the 5-HT6 receptor, as represented by the formula (I) and its derivatives. The patent encompasses the preparation of these compounds, including prodrugs, tautomers, stereoisomers, polymorphs, solvates, hydrates, metabolites, N-oxides, and pharmaceutically acceptable salts. These compounds have been identified as useful in the treatment and prevention of various disorders related to 5-HT receptor functions.
Career Highlights
Anil Chindhe works at Suven Life Sciences Limited, a leading pharmaceutical company dedicated to innovation in drug discovery and development. His work at Suven Life Sciences showcases his commitment to advancing medical science through innovative research.
Collaborations
Throughout his career, Anil has collaborated with esteemed professionals, including Ramakrishna Nirogi and Anil Karbhari Shinde. These partnerships exemplify the spirit of innovation and teamwork within the pharmaceutical research community.
Conclusion
Anil Kashinath Chindhe’s contributions to the field of pharmaceuticals demonstrate the impact of innovative thinking on healthcare. His patent for sulfone compounds serves as a testament to his dedication and expertise, promising potential breakthroughs in treating disorders associated with 5-HT receptor functions.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile